| Name | Number of Reports | Reference(s) | Data Source | |
|---|---|---|---|---|
| 1 | ledipasvir, sofosbuvir drug combination | FAERS: 5 | US FAERS | |
| 2 | Viekira Pak | FAERS: 4 | US FAERS | |
| 3 | entecavir | FAERS: 3 | US FAERS | |
| 4 | sofosbuvir-velpatasvir drug combination | FAERS: 2 | US FAERS | |
| 5 | Dasatinib | FAERS: 1 | US FAERS | |
| 6 | Mycophenolic Acid | FAERS: 1 | US FAERS | |
| 7 | Naltrexone | FAERS: 1 | US FAERS | |
| 8 | Sofosbuvir | FAERS: 1 | US FAERS | |
| 9 | Temozolomide | FAERS: 1 | US FAERS | |
| 10 | Teriparatide | FAERS: 1 | US FAERS | |
| 11 | elbasvir-grazoprevir drug combination | FAERS: 1 | US FAERS | |
| 12 | Lorazepam | OFFSIDES | ||
| 13 | N-(3-amino-1-(cyclobutylmethyl)-2,3-dioxopropyl)-3-(2-((((1,1-dimethylethyl)amino)carbonyl)amino)-3,3-dimethyl-1-oxobutyl)-6,6-dimethyl-3-azabicyclo(3.1.0)hexan-2-carboxamide | Canada Vigilance: 1 | Canada Vigilance | |
| 14 | Tranexamic Acid | OFFSIDES | ||
| 15 | Ubiquinone | OFFSIDES |
Page last updated at 2020-05-25 10:01:57 (Asia/Shanghai) | You are visitor No. 120295
Copyright © 2019-2020 Laboratory of Molecular Modeling and Design, Shanghai Key Laboratory of New Drug Design, School of Pharmacy, East China University of Science and Technology. All rights reserved.